Fulcrum Therapeutics, Inc.·4

Feb 13, 4:15 PM ET

Tourangeau Greg 4

4 · Fulcrum Therapeutics, Inc. · Filed Feb 13, 2023

Insider Transaction Report

Form 4
Period: 2023-02-09
Tourangeau Greg
Principal Accounting Officer
Transactions
  • Award

    Stock Option (right to buy)

    2023-02-09+16,10016,100 total
    Exercise: $12.59Exp: 2033-02-08Common Stock (16,100 underlying)
Footnotes (1)
  • [F1]This option was granted on February 9, 2023 and is is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2023, subject to the reporting person's continued service on each such vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION